Search

Your search keyword '"Stefano Pulini"' showing total 66 results

Search Constraints

Start Over You searched for: Author "Stefano Pulini" Remove constraint Author: "Stefano Pulini" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
66 results on '"Stefano Pulini"'

Search Results

1. Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia

3. P965: STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA

5. Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma

6. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

7. Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

8. A case of vaccine-induced immune thrombotic thrombocytopenia with massive artero-venous thrombosis

9. Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting

10. Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis

11. 29Detection of myocardial iron overload with magnetic resonance by native T1 and T2* mapping using a segmental approach

12. Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma

13. Sensitivity of cutaneous chronic myelomonocytic leukaemia lesions to hypomethylating treatment

14. PB2389 UNDERDOSING DEFERIPRONE IN TM: MYTH OR REALITY?

15. Familial acquired thrombotic thrombocytopenic purpura: immunogenetic link with HLA-DRB1*11 and DQB1*03 antigens

16. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

17. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

18. Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

19. Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study

20. Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Real Life Experience

21. Multicenter Validation of the Magnetic Resonance T2* Technique for Quantification of Pancreatic Iron

22. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

23. Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and 'novel agent' therapy

24. Carboplatin and Gemcitabine in the Palliative Treatment of Stage IV Non-Small Cell Lung Cancer: Definitive Results of a Phase II Trial

25. Prognostic CMR parameters for heart failure and arrhythmias in large cohort of well treated thalssemia major patients

26. New Myeloma Diagnostic Criteria: To Treat or Not to Treat? Monocentric Experience of 220 Newly Multiple Myeloma Diagnosed Patients Retrospectively Analyzed

27. Early Mortality in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Agents

28. Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma

29. Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

30. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

31. The Dream of a Cure in Multiple Myeloma: A 15-Year Single Center Retrospective Study

32. Paroxysmal nocturnal hemoglobinuria after autologous stem cell transplantation: extinction of the clone during treatment with eculizumab - pathophysiological implications of a unique clinical case

33. Outcome and toxicity in the modern era of new drugs for multiple myeloma: A reappraisal for comparison with future investigational trials

34. Preferential patterns of myocardial iron deposit by multislice multiecho T2* CMR in thalassemia major patients

35. Lesional skin chemokine CTACK/CCL27 expression in mycosis fungoides and disease control by IFN-alpha and PUVA therapy

36. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies

37. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

38. Improvement of Quality of Response After Additional Therapy Before Autologous Stem Cell Transplant is not Translated in Improvement of Global Outcome of Multiple Myeloma Patients

39. Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study

40. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides

41. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

42. Hypothyroidism and Cardiac Complications In Thalassemia Major Patients

43. Heterogeneity and Peculiarities Of a Small Series Of Patients Affected By Paroxysmal Nocturnal Hemoglobinuria Treated With Eculizumab

44. Low Dose Bexarotene and Ultraviolet A Photochemotherapy (PUVA) In a Prospective Phase II Clinical Study for Refractory and/or Resistant Cutaneous T Cell Lymphomas (CTCL)

45. Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM: a Phase I-II Study

46. Extramedullary Relapses After Stem Cell Transplantation in Multiple Myeloma

47. Leuco-Thrombocytopenia Due to Splenomegaly in a Patient Affected by Retroperitoneal Fibrosis

48. Alemtuzumab in Combination with Interferon-α or Gemcitabine in Aggressive and Advanced Cutaneous T-Cell Lymphomas: Report of Preliminary Results

49. Oncological and Hematological Neoplasms: Concomitant Oral Anticoagulation Therapy

50. Pegylated Liposomal Doxorubicin in Primary Cutaneous Lymphomas: Efficacy, Safety, and Low Rate of Palmar-Plantar Erythrodysesthesia

Catalog

Books, media, physical & digital resources